Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 79.5% in August

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a significant drop in short interest in August. As of August 14th, there was short interest totaling 770 shares, a drop of 79.5% from the July 30th total of 3,749 shares. Based on an average daily trading volume, of 34,611 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

BOLT has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Friday, July 17th. Rodman & Renshaw started coverage on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Bolt Biotherapeutics has an average rating of “Hold” and a consensus target price of $14.50.

Hedge Funds Weigh In On Bolt Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC lifted its holdings in shares of Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after acquiring an additional 2,448 shares during the period. Shay Capital LLC purchased a new position in Bolt Biotherapeutics in the third quarter valued at approximately $85,000. Susquehanna International Group LLP acquired a new position in Bolt Biotherapeutics during the third quarter valued at approximately $89,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in Bolt Biotherapeutics during the fourth quarter worth approximately $112,000. Finally, T3 Companies LLC purchased a new stake in Bolt Biotherapeutics during the fourth quarter worth approximately $208,000. 86.70% of the stock is currently owned by institutional investors and hedge funds.

Bolt Biotherapeutics Price Performance

BOLT stock traded up $0.08 during midday trading on Thursday, hitting $4.00. 7,708 shares of the stock were exchanged, compared to its average volume of 25,593. The stock has a market cap of $7.72 million, a price-to-earnings ratio of -0.24 and a beta of 1.18. Bolt Biotherapeutics has a fifty-two week low of $3.13 and a fifty-two week high of $7.20. The stock’s 50-day moving average price is $3.90 and its 200-day moving average price is $4.43. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18). Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%.The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.50 million. Research analysts predict that Bolt Biotherapeutics will post -11.1 earnings per share for the current year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.